Non-macrocyclic GLP-1 agonist peptides treat NAFLD while reducing gastrointestinal side effects that limit dosing and compliance.
Controlled oral or IV nitrate and nitrite dosing lowers exercise oxygen consumption and supports glucose control without methemoglobinemia.
A paraben-free fexofenadine suspension uses alternative preservatives and pH control to maintain microbial stability and bioequivalence.
Hydrogen-assisted oxygen scavenging keeps nitric oxide dissolved in liquid stable longer, reducing oxidation to NO2 in aqueous solutions.